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Superior Antitumor Activity of a Novel Bispecific Antibody
CotargetingHumanEpidermalGrowthFactorReceptor 2 and
Type I Insulin-like Growth Factor Receptor
Chao Chen1, Yanyu Zhang1, Yu Zhang1, Jingjing Li1, Sai Wah Tsao2, and Mei-Yun Zhang1
Abstract
The humanized anti-HER2 monoclonal antibody (mAb) trastuzumab (Herceptin; Genentech) effectively
inhibits human epidermal growth factor receptor 2 (HER2)-positive breast tumors. However, many
patients responding to treatment often develop resistance. Cross-talk between type I insulin–like growth
factor receptor (IGF-IR) and HER2 and elevated IGF-IR signaling have been implicated in tumor cell
resistance to trastuzumab therapy. Previously, we reported that the anti-IGF-IR mAb m590 inhibits
proliferation and migration of breast cancer MCF-7 cells in vitro. Here, we generated a "knobs-into-holes"
bispecific antibody (Bi-Ab) against HER2 and IGF-IR by engineering trastuzumab and m590. We compared
the effects of Bi-Ab treatment in vitro and in SKOV-3 HER2- and IGF-IR–overexpressing cancer xenograft
mouse model with those of m590 and trastuzumab treatment alone or in combination. Bi-Ab effectively
inhibited proliferation of HER2- and IGF-IR–overexpressing ovarian cancer SKOV-3 cells in vitro by
ablating receptor phosphorylation and downstream PI3K/Akt and mitogen-activated protein kinase
signaling. Bi-Ab more effectively inhibited cancer growth in SKOV-3 HER2- and IGF-IR–overexpressing
cancer xenograft mouse model than m590 and trastuzumab alone or in combination. Mice bearing SKOV-3
HER2- and IGF-IR–overexpressing xenografts showed extensive and sustainable tumor regression when
treated with Bi-Ab. Our results suggest that Bi-Ab has superior antitumor activity compared with
monospecific antibodies, and cotargeting HER2 and IGF-IR may be clinically beneficial in minimizing
the acquired resistance to trastuzumab therapy. Mol Cancer Ther; 1–11. 2013 AACR.
Introduction
HER2, encoded by the ErbB2 gene, is a member of the
EGFR/ErbB family (1). HER2 is structurally similar to
other EGF receptor (EGFR) family members, including
HER1 (EGFR, ErbB1), HER3 (ErbB3), and HER4 (ErbB4),
and also acts as a receptor tyrosine kinase (RTK).
Homodimerization of HER1 and HER4 upon ligand
binding activates intrinsic, intracellular protein-tyro-
sine kinase activity, resulting in receptor autophosphor-
ylation and downstream signaling, including signaling
pathways such as, the Phosphoinositide 3-kinase
(PI3K), the c-Jun N-terminal kinase (JNK), and the
mitogen-activated protein kinase (MAPK), which pro-
mote DNA synthesis, cell proliferation, and inhibition
of cell apoptosis. HER3 does not have a tyrosine kinase
domain, so it transfers signals upon ligand binding
through heterodimerization with other EGFR family
members that have kinase activity. Unlike HER1, HER3,
and HER4, HER2 is unable to bind ligands and form
homodimers. However, HER2 possesses tyrosine kinase
activity, and seems to be the major signaling partner for
EGFR family members through the formation of hetero-
meric complexes (2). Heterodimerization between two
EGFR family members requires ligand binding (3, 4),
but the crystal structure of a truncated HER2 ectodo-
main suggests that HER2 is constitutively in the acti-
vated conformation and readily interacts with HER3
mostly and other EGFR family members (5). Overex-
pression of HER2 promotes ligand-independent forma-
tion of a HER2/HER3 receptor complex, a major onco-
genic driver in HER2-overexpressing breast tumor cells
(6). Cleavage of HER2 by the extracellular protease,
ADAM10, produces the HER2 ectodomain and a trun-
cated, constitutively active HER2 receptor (p95HER2)
shown to drive carcinogenesis (7). HER2 overexpression
is associated with strong activation of the PI3K path-
way, which stimulates cell proliferation by activating
the protein kinase Akt and downregulating the cyclin-
dependent kinase inhibitor, p27 (8). HER2 can also
activate the MAPK pathway via interaction with SHC
and GRB2 adaptor proteins (9). Overexpression of
HER2 was found in breast and ovarian cancers, and
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associated with cancer metastasis (10–12), poor clinical
outcome, and decreased survival rate (13–15).
Type I insulin-like growth factor receptor (IGF-IR) is a
tyrosine kinase receptor composed of 2 a subunits and 2 b
subunits. Upon binding to either of the two ligands,
insulin-like growth factor I (IGF-I) or IGF-II, the extracel-
lular domain of the a chains induces tyrosine autopho-
sphorylation of the b chains in the cytoplasm. This
activates the kinase activity of IGF-IR, and triggers down-
stream signaling via the PI3K/Akt and Ras/MAPK
pathways, resulting in increased cell survival and cell
proliferation (16, 17). Elevated IGF-IR is found in many
tumor malignancies, including breast, prostate, and lung
cancers (18, 19). In addition, overexpression of IGF-IR has
been associated with disease progression and cancer
metastasis (20, 21).
HER2 is awidely used diagnosticmarker and validated
target for therapy. The humanized anti-HER2monoclonal
antibody (mAb) trastuzumab (Herceptin; Genentech) has
been effective in treating HER2-overexpressing breast
cancers (22, 23). Binding of trastuzumab to HER2 causes
internalization and degradation of the receptor in SKBR3
and MDA453 cells (24). Trastuzumab binds to domain IV
of the extracellular segment of HER2, leading to disrup-
tion of HER2/HER3 dimerization and ablation of down-
stream PI3K/Akt signaling (6). Trastuzumab can also
inhibit cleavage of HER2 ectodomain in breast cancer
cells, thus block the generation of a constitutively active
truncated receptor (p95HER2; refs. 7, 25, 26). In addition,
Fc-mediated antibody-dependent cell-mediated cytotox-
icity (ADCC) may partially contribute to the antitumor
activity of trastuzumab in vivo (27).
Only 25% to 30% of the patients with breast cancer
overexpressHER2, and patients treatedwith trastuzumab
can develop resistance as the disease progresses. Various
mechanisms may account for this resistance, which likely
involve the PI3K/Akt pathway, including elevatedHER2-
associated receptors and other receptors (28, 29), cross
activation between HER2 and other receptors (30–32),
blockage of trastuzumab by membrane-associated glyco-
proteins such as mucin-4, removal of the trastuzumab
epitope by cleavage or loss of HER2 expression, and
increased HER2 expression. Accumulating evidence
shows that cross-talk between HER2 and IGF-IR, includ-
ing receptor heterodimerization and transactivation, and
elevated IGF-IR signaling are associatedwith trastuzumab
resistance (31, 33–35). Overexpression of IGF-IR in HER2–
overexpressing breast cancer cell lines results in trastuzu-
mab resistance in vitro (36). Inhibition of IGF-1R activity
enhances the response to trastuzumab in HER-2–positive
breast cancer cells (37). A phase II clinical trial of patients
with HER2-positive breast cancer revealed that overex-
pression of IGF-IR in the primary tumor was associated
with resistance to trastuzumab (38). Therefore, cotargeting
IGF-IR and HER2 may be clinically beneficial in minimiz-
ing the acquired resistance to trastuzumab therapy.
We previously described a human/mouse chimeric
mAb m590 that specifically bound with high affinity to
IGF-IR and blocked the binding of IGF-I and IGF-II to IGF-
IR. This inhibited ligand-inducedphosphorylation of IGF-
IR in breast cancer MCF-7 cells (39). In this study, we
generated abispecific antibody (Bi-Ab) by engineering the
m590 and trastuzumab, and tested Bi-Ab in vitro and in
SKOV-3 HER2- and IGF-IR-overexpressing xenograft
mouse model. We found that cotargeting HER2 and
IGF-IR with Bi-Ab was more effective than targeting
HER2 or IGF-IR alone with the monospecific antibodies
or cotargeting HER2 and IGF-IR with a combination
(Comb) of the two monospecific antibodies in ablating
tumor cell proliferation in vitro and in vivo.
Materials and Methods
Cell lines, antibodies, and chemicals
Breast cancer MCF-7 cells were cultured in Dulbecco’s
Modified Eagle Medium (Invitrogen) supplemented with
10% heat-inactivated FBS and 1% penicillin/streptomy-
cin. Ovarian cancer SKOV-3 cells were cultured in
McCoy’s 5A medium (Hyclone) supplemented with
10% heat-inactivated FBS and 1% penicillin/streptomy-
cin. BothMCF-7 andSKOV-3 cell lineswere obtained from
National Cancer Institute, NIH (Bethesda, MD). No
authentication was done by the authors. The following
primary mAbs were purchased from Cell Signaling Tech-
nology: rabbit anti-Phospho-AKT (Thr308; C31E5E), rab-
bit anti-Phospho-p44/42 MAPK (ERK1/2; Thr202/
Tyr204; D13.14.4E) XP, rabbit anti-Akt (pan; 11E7), rabbit
anti-P44/42 MAPK (ERK1/2; 137F5), and rabbit anti-
GAPDH mAb (14C10). The secondary antibodies were
purchased from Jackson ImmunoResearch. Xenolight D-
luciferin was purchased from Caliper Life Sciences.
Expression and purification of recombinant IGF-IR
and HER2 ectodomains
The gene encoding the extracellular domain (ectodo-
main) of IGF-IR was amplified from the pBlueScript-IGF-
IR construct P08069 (39), and subcloned into the pSec-
Tag2C vector at the EcoR I and Not I sites. The gene
encoding HER2 ectodomain was amplified from SKOV-
3 cell line by reverse transcriptase PCR, and subsequently
cloned into the pSecTag2A vector at the Xho I and Sfi I
sites. Both constructs were confirmed by DNA sequenc-
ing. Recombinant ectodomains of IGF-IR and HER2 were
produced by transient transfection of 293T cells. Expres-
sion in transfectants was enhanced by the transduction of
vaccinia virus vTF7.3 encoding bacteriophage T7 RNA
polymerase. Seventy-two hours posttransfection, culture
supernatants were collected andHis-tagged ectodomains
purified by immobilized metal affinity chromatography.
Construction of "knobs-into-holes" CH3 variants
The humanized trastuzumab heavy chain variable
region and light chain [DrugBank: trastuzumab
(DB00072) (BIOD00098, BTD00098)] genes were synthe-
sized and cloned into themammalian expression plasmid
pDR12 containing human immunoglobulin G (IgG)-1
heavy chain genomic DNA constant regions. Two
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mutations were introduced in the CH3 domains of
pDR12-trastuzumab (T366Y) and pDR12-m590 (Y407T)
using a site-directed mutagenesis kit (Stratagene). The
primers for the mutagenesis were: T366Y-F: 50-CCAGGT-
CAGCCTGTACTGCCTGGTCAAAG-30, andT366Y-R: 50-
CTTTGACCAGGCAGTACAGGCTGACCTGG-30; and
Y407T-F: 50-CTCCTTCTTCCTCACCAGCAAGCTCACC-
G-30, and Y407T-R: 50- CGGTGAGCTTGCTGGTGAG-
GAAGAAGGAG -30. The mutations were confirmed by
DNA sequencing. The resultant plasmids were designat-
ed as pDR12-trastuzumab-366 and pDR12-m590-407,
respectively.
Expression and purification of trastuzumab and
m590, and Bi-Ab
Trastuzumab and m590 were expressed by transient
transfection of 293F cells (Invitrogen) with recombinant
plasmids pDR12-trastuzumab and pDR12-m590, respec-
tively. Bi-Ab was expressed by transiently cotransfecting
293F cells with pDR12-trastuzumab-366 and pDR12-
m590-407 plasmid DNA. Recombinant antibodies were
purified from the culture supernatants by protein A (GE
Healthcare) affinity purification.
Indirect ELISA
Recombinant ectodomains of IGF-IR orHER2 (2mg/mL
in both cases) were coated on 96-well high-binding ELISA
plates at 4C overnight. The plates were washed and
blocked with 3% bovine serum albumin in PBS at 37C
for 2hours. Two-fold seriallydilutedmAb trastuzumabor
m590 was added to the wells and the bound mAbs were
detected by horseradish peroxidase (HRP)-conjugated
anti-human Fc as secondary antibody and 3,3’,5,5’-Tetra-
methylbenzidine (TMB) substrate. Optical density at 450
nm (OD450nm)wasmeasured after color development at
room temperature for 30 minutes. In the case of Bi-Ab,
recombinant IGF-IR ectodomains were coated on the
plates. Following addition of 2-fold serially diluted anti-
bodies and incubation at room temperature for 2 hours,
plateswerewashed andbiotinylatedHER2 ectodomain (2
mg/mL) was added to each well. Bound HER2 ectodo-
mainswere detected byHRP-conjugated streptavidin and
TMB substrate.
Western blotting
MCF-7 or SKOV-3 cells in complete medium were
seeded in 6-well plates. When cells reached 70% to 80%
confluence, they were incubated in serum-free medium
overnight. Cells were treated with antibodies for 30
minutes, followed by addition of 1.5 nmol/L IGF-I and
further incubation for 30 minutes. Cells were then lysed
and 10 mL of cell lysates from each sample was resolved
by 12% SDS-PAGE. Once the proteins were transferred,
polyvinylidene difluoride membranes were blocked
with 5% skim milk in PBS for 30 minutes, incubated
with primary antibodies, and then secondary antibo-
dies. The membranes were extensively washed after
each incubation step. The Western blot signal was
detected by Western Bright ECL-HRP substrate
(Advansta).
Flow cytometry
MCF-7 or SKOV-3 cells were detached using enzyme-
free cell-disassociation buffer (Invitrogen), washed twice
with PBS, and incubated at 4C for 2 hourswith antibodies
in fluorescence-activated cell sorting (FACS) buffer (1%
FBS in PBS). Cell surface bound antibodies were detected
using phycoerythrin conjugated to anti-human Fc by
incubation at 4C for 1 hour followed by washing twice
with FACSbuffer andfixationwith 2%paraformaldehyde
in FACS buffer. The stained cells were analyzedwith a BD
flow cytometer and FlowJo software.
ADCC assay
The flow cytometry-based ADCC assay has been
described previously (40). Here, we used SKOV-3 cells
as target cells and healthy human volunteers peripheral
blood mononuclear cells (PBMC) as effector cells at an
E/T ratio of 20/1. Briefly, SKOV-3 cells were stained with
PKH-67 and then mixed with antibodies and PBMCs.
Following 2 hours of incubation, 7-Aminoactinomycin
D (7-AAD) was added to the mixture. Following several
washes, the samples were analyzed by FACS AriaIII flow
cytometer using BD FACS Diva software. Percentage of
cell death was determined by software analysis of four
identifiable cell populations, live effector cells (no dye),
dead effector cells (7-AAD positive), live target cells
(PKH-67 positive), and dead target cells (PKH-67 and 7-
AAD double positive). Percentage of ADCC was calcu-
lated as [(% experimental lysis%spontaneous lysis)/(%
maximum lysis  % spontaneous lysis)]  100, in which
"% spontaneous lysis" referred to percentage of dead
target cells mixed with effectors in the absence of anti-
bodies, and "% maximum lysis" referred to percentage of
dead target cells mixed with effectors in the presence of
1% Triton X-100, and "% experimental lysis" referred to
percentage of dead target cells mixed with effectors in the
presence of antibodies. The assay was performed in
duplicate and repeated once. One representative set of
data was shown in this report.
Cell proliferation assay
Antibodies were serially diluted in culture medium
containing 2% FBS and mixed with equal volume of
SKOV-3 cells containing 3 nmol/L IGF-I. Cell/Ab mix-
tureswere thenplated onto 96-well cell cultureplateswith
a final concentration of 2,000 cells perwell and 1.5 nmol/L
IGF-I. The plates were incubated at 37Cwith 5% CO2 for
72 hours, and cell proliferation level was detected by Cell
Titer 96 Aqueous Non-Radioactive Cell Proliferation
Assay Kit (Promega).
Generation of the luciferase-expressing SKOV-3
stable cell line
293T cells were transiently cotransfected with recom-
binant plasmid encoding HIV-1 Gag and polymerase
Bispecific Antibody Cotargeting HER2 and IGF-IR
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(Gag-pol), Luc-expressing plasmid, and vesicular sto-
matitis virus (VSV) backbone plasmid at a ratio of 2/2/1
(Gag-pol/Luc/VSV). Thirty-six to 48 hours posttrans-
fection, culture supernatant containing Luc-lentivirus
was collected, and equally mixed with fresh culture
medium followed by addition of polybrene to a final
concentration of 8 mg/mL. Nine milliliters of the mix-
ture were added to SKOV-3 cells seeded in 100 mm
dishes and incubated at 37C for 6 hours in 5% CO2.
Three milliliters of culture medium containing 8 mg/mL
polybrene were then added to the dish. Following
overnight incubation, infection medium was removed
and cells cultured in fresh McCoy’s 5A medium con-
taining 1 mg/mL puromycin. After three to five pas-
sages, limiting dilution was performed and single cell
clones were screened by luciferase assay. The single cell
clone expressing the highest level of luciferase was
expanded and titrated by imaging in a 96-well plate.
Establishment of a breast tumor xenograft mouse
model and the mouse study
This study was approved by University of Hong Kong
(HKU; Hong Kong, China) Committee on Using Live
Animals in Teaching and Research (CULATR # 2514-
11). Nude BALB/c female mice, 4–6-weeks-old, were
obtained from theAnimalCentre of theHKU. To establish
a breast cancer xenograft mouse model, a pilot exper-
iment was carried out by subcutaneously injecting dif-
ferent numbers of SKOV3-Luc cells into nude mice and
imaging the mice at different time points. The optimal
cell numbers that yielded sustainable and increasing
luminescence intensity in the regions of interest (ROI)
were determined.
The mouse study was carried out as follow: on day 0,
SKOV-3-Luc cells were resuspended in plainMcCoy’s 5A
medium and 3 million of the cells were injected subcuta-
neously into each nude mouse. On day 1, KETAMINE/
XYCAZINE/PBS at a ratio of 1/1.2/7.8weremixedand40
mL (2.5 mL/g body weight) of the anesthetic mixture was
injected subcutaneously into eachmouse. D-luciferin (100
mL) at a concentration of 30 mg/mL in Dulbecco’s Phos-
phate-Buffered Saline (DPBS; 5 ml/g body weight) was
then injected intraperitoneally into each mouse (each
mouse received 150mg luciferin/kg bodyweight). About
15 minute after injection, mice were imaged for lumines-
cence intensity in the ROI using Xenogen IVIS 100 in vivo
imaging system.Micewere then randomized, so that each
group of mice had approximately the same average lumi-
nescence intensity. Each group had sevenmice and a total
of four groups were formed corresponding to trastuzu-
mab, m590, Bi-Ab, and Comb treatment conditions. Each
antibody (100 mg) or antibody combination (100 mg total)
were injected intraperitoneally into eachmouse on days 1,
4, 6, and 8.Mouse imagingwas repeated ondays 4, 6, 8, 11,
15, 25, and 35. A control group had fivemice andwere not
treated with any antibodies after injection of tumor cells,
but imaged at the same time with antibody-treated
groups.
Results
Bi-Ab cotargets IGF-IR and HER2
We used the "knobs-into-holes" approach to generate
an anti-IGF-IR/anti-HER2 hybrid IgG (41–43). A "knob"
mutant was created by replacing a threonine with tyro-
sine (T366Y) in the CH3 domain of trastuzumab. A
"hole" mutant was made by replacing a tyrosine with
threonine (Y407T) in the CH3 domain of m590. Cotrans-
fection of 293F cells with the "knob" and "hole" plasmids
resulted in the production of stable heterodimers that
exhibited bispecificity for both HER2 and IGF-IR
(Fig. 1). The Bi-Ab bound to recombinant IGF-IR and
HER2 ectodomains (Fig. 1C) and to overexpressed,
membrane-associated IGF-IR and HER2 on SKOV-3
cells (Fig. 1B and D). Compared with breast cancer
MCF-7 cells used in our previous study, ovarian cancer
SKOV-3 cells express a high level of HER2 and a modest
level of IGF-IR (Fig. 1A). Similar to the two parental
antibodies, m590 and trastuzumab, Bi-Ab bound to
SKOV-3 in a dose-dependent manner (Fig. 1D). More-
over, flow cytometry analysis revealed that trastuzu-
mab and Bi-Ab have a similar binding profile, which
shows two peaks in the histogram (Fig. 1B), suggesting
that cell surface HER2 proteins may have multiple
conformational or organizational states.
Bi-Ab inhibits receptor phosphorylation and
downregulates downstream PI3K/Akt and MAPK
signaling
We previously reported that m590 blocked ligand-
induced IGF-IR phosphorylation in breast cancer MCF-
7 cells (39), and inhibited MCF-7 cell proliferation and
migration (44). We extended these findings in this study
by analyzing the downstream signaling of IGF-IR. We
found that m590 inhibited ligand-induced phosphoryla-
tion of Akt and extracellular signal–regulated kinase
(ERK) in MCF-7 cells (Fig. 2A), and synergized with
trastuzumab in inhibiting ligand-induced Akt phosphor-
ylation in MCF-7 cells (Fig. 2B). Next, we compared the
effects of Bi-Ab, m590, and trastuzumab on phosphory-
lation of IGF-IR in SKOV-3 cells (Fig. 2C) with down-
streamsignaling inMCF-7 (Fig. 2D) andSKOV-3 cells (Fig.
2E) in the presence of ligand (IGF-I) or absence of ligand
(Fig. 2F). Both m590 and Bi-Ab inhibited phosphorylation
of IGF-IR in SKOV-3 cells compared with nonspecific
human IgG control. Treatmentwith trastuzumaborComb
did not result in decreased levels of phosphorylated IGF-
IR in SKOV-3 cells (Fig. 2C). In MCF-7 cells, m590 and Bi-
Ab, as well as Comb inhibited ligand-induced phosphor-
ylation of Akt, but only Bi-Ab inhibited ligand-induced
phosphorylation of ERK (Fig. 2D). Treatment with tras-
tuzumab slightly enhanced ligand-induced phosphory-
lation of Akt in MCF-7 cells (Fig. 2D, lane 2). None of the
antibodies showed inhibitory effects on ligand-induced
phosphorylation of Akt and ERK in SKOV3 cells at the
antibody concentration (100 mg/mL) tested (Fig. 2E).
When we compared the effects of Bi-Ab, m590, and
trastuzumab on phosphorylation of ERK in MCF-7 and
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SKOV-3 cells (Fig. 2F) in the absence of ligand, we found
that in MCF-7 cells, both m590 and Bi-Ab inhibited ERK
phosphorylation, and Comb treatment slightly reduced
ERK phosphorylation (data not shown), but in SKOV-3
cells, Bi-Ab inhibited ERK phosphorylation (Fig. 2F), and
this inhibition was dose dependent (Fig. 2G). Trastuzu-
mab did not have inhibitory effect on ERK phosphoryla-
tion in both cell lines (data not shown; Fig. 2F). These
results indicate that coexpression of both high levels of
HER2 and IGF-IR in cancer cells raise the bars for anti-
bodies to interfere with the receptor phosphorylation and
downstream signaling, especially when the ligand (IGF-I)
is present. Trastuzumab was ineffective in inhibiting
phosphorylation of Akt and ERK in both MCF-7 and
SKOV-3 cells in the presence or absence of IGF-I. Bi-Ab,
m590, and Comb were equally effective in inhibiting
phosphorylation of Akt and ERK in MCF-7 cells in the
absence of ligand (data not shown) and in inhibiting
ligand-induced Akt phosphorylation in MCF-7 cells (Fig.
2D), but Bi-Abwasmore effective thanm590 andComb in
inhibiting ligand-induced ERK phosphorylation in MCF-
7 cells (Fig. 2D), and more effective than Comb in inhibit-
ing ERK phosphorylation in SKOV-3 cells in the absence
of ligand (Fig. 2F).
Bi-Ab more effectively inhibits cancer cell
proliferation than trastuzumab and m590 in vitro,
and preserves ADCC activity
The attenuation of the PI3K/Akt and MAPK pathways
by Bi-Ab prompted us to analyze the effects of Bi-Ab
on cancer cell proliferation. Bi-Ab treatment effectively
inhibited SKOV-3 cell proliferation in vitro (Fig. 3A).
Notably, although Comb treatment showed enhanced
inhibition of SKOV-3 proliferation compared with
trastuzumab treatment alone, both treatment conditions
were significantly less potent than Bi-Ab, especially
at high antibody concentrations (over 25 mg/mL; Fig.
3A). M590 inhibited SKOV-3 cell proliferation, but its
effect decreased sharply asm590 concentration decreased
(Fig. 3A).
To investigate whether "knob" and "hole" mutations
affected Fc-mediated effector function, we tested Bi-Ab
for ADCC activity in a flow cytometry-based assay
using SKOV-3 as target cells and healthy human PBMCs
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Figure 1. Flow cytometry of SKOV-3 and MCF-7 cells stained with m590 or trastuzumab and characterization of Bi-Ab for binding to recombinant HER2 and
IGF-IR ectodomains andmembrane-associated HER2 and IGF-IR in comparison with m590 and trastuzumab. A, flow cytometry of breast cancer MCF-7 and
ovarian cancer SKOV-3 cells stained with m590 and trastuzumab at 10 mg/mL. B, simultaneous binding of Bi-Ab to recombinant IGF-IR and HER2
ectodomains by indirect ELISA. Recombinant IGF-IR ectodomain was coated in microplates. Three-fold serially diluted Bi-Ab, trastuzumab, and m590 were
added to the wells followed by addition of 100 ng per well of biotinylated recombinant HER2 ectodomain. Bound HER2 ectodomain was detected by HRP
conjugated to streptavidin andTMB.C, histogramoverlay of SKOV-3 cells stainedwithm590, trastuzumab, andBi-Abat 2 and10mg/mL.D, binding kinetics of
Bi-Ab, m590, and trastuzumab to membrane-associated IGF-IR and HER2 on SKOV-3 cells. Mean fluorescence intensity (MFI) of SKOV-3 cells stained with
the antibodies at different concentrations was measured.
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as effector cells. The assay revealed that Bi-Ab had
ADCC activity comparable with or slightly higher than
that of m590, trastuzumab, and the combination of m590
and trastuzumab (Comb; Fig. 3B). Notably, percentage
of ADCC with Bi-Ab was significantly higher than that
with Comb at 1 mg/mL (P < 0.05). These results suggest
that Bi-Ab remains effective in killing HER2- and/or
IGF-IR–overexpressing tumor cells through ADCC in
vivo.
Bi-Ab inhibits tumor growth in SKOV-3 HER2- and
IGF-IR–overexpressing xenograft mouse model
To establish a HER2- and IGF-IR–overexpressing can-
cer xenograftmousemodel for testing the effect ofBi-Ab in
vivo, we generated a SKOV-3-Luc stable cell line expres-
sing luciferase. We tested Bi-Ab, m590, trastuzumab, and
Comb in this mouse model following the protocol shown
in Fig. 4A. Therewere a total of four experimental groups,
andeachgrouphad sevennudemice.Acontrol group that
had five nude mice was included in the study. Three
million of SKOV-3-Luc cellswere injected subcutaneously
to each nude mouse, and antibodies (100 mg per mouse)
were injected intraperitoneally on days 1, 4, 6, and 8
postinoculations. Mouse body weight and luminescence
intensity in the ROI were measured on days 1, 4, 6, and 8
before antibody injections, and repeatedondays 11, 15, 25,
and 35 postinoculations. The average body weight of Bi-
Ab–treated mice did not decrease throughout the study,
whereas the averagemouse bodyweight of the other three
experimental groups decreased on day 4. Nevertheless,
therewasno significant difference in average bodyweight
among the four groups at comparable time points (data
not shown).
The average luminescence intensities varied across all
the experimental groups (Fig. 4B). Notably, the Bi-Ab–
treated group experienced a dramatic inhibition of
tumor growth that lasted for a much longer time com-
pared with the other three groups. The Bi-Ab group
showed significantly lower average luminescence inten-
sities than the m590 group (P < 0.001) from day 6 to day
35, the end of the mouse study, whereas the Comb
group only showed significantly lower average lumi-
nescence intensities than the m590 group on days 6, 8,
and 11, and the trastuzumab group only showed
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significant lower average luminescence intensities than
the m590 group on days 8 and 11 (Fig. 5A). The aver-
age luminescence intensity of the m590 group also
decreased on day 11, and further decreased on day
15, but returned to high levels on days 25 and 35. These
decreases may not be caused bym590 treatment because
the control group also showed slightly decreases in
average luminescence intensity on day 11 and 15 (Fig.
4B). The Comb group showed relapse (increased aver-
age luminescence intensity) starting on day 25, whereas
the trastuzumab group relapsed earlier on day 15. The
average luminescence intensity of the Bi-Ab on day 35
slightly increased, but it was still significantly lower
than that of the m590 group (Fig. 5A).
We then investigated individual mouse in each group
and counted the number of mouse that had 2-fold higher
luminescence intensity than the baseline level (no
inoculation; Fig. 5B). The Bi-Ab group showed early
decrease in luminescence intensity. Five out seven mice
in the Bi-Ab group had luminescence intensities below 2-
fold of the baseline level on day 4, whereas only three out
of seven mice in the Comb and trastuzumab groups had
the same low levels of luminescence intensity on day 4
(Fig. 5B). The rest two mice in the Bi-Ab showed lumi-
nescence intensities below 2-fold of the baseline level on
days 8 and 15, and the luminescence intensities of all mice
in the Bi-Ab group remained low till the end of the mouse
study except that one mouse relapsed on day 35 (Fig. 5B).
Five out of seven mice in the Comb group showed lumi-
nescence intensities below 2-fold of the baseline level on
days 6 and 8, but one of these fivemice in the Comb group
relapsed on day 35. Six out of seven mice in the trastu-
zumab group showed luminescence intensities below 2-
fold of the baseline level on day 8, but thesemice relapsed
one by one as the study progressed. There was only one
mouse left in the trastuzumab group that had the lumi-
nescence intensity below 2-fold of the baseline level on
day 35 (Fig. 5B). None of mice in the m590 ever exhibited
luminescence intensity below 2-fold of the baseline level
throughout the study. These results indicate that dual
targeting HER2 and IGF-IR is more effective than single
targeting in inhibiting HER2- and IGF-IR–overexpressing
tumor growth and postponing tumor relapse in vivo, and
Bi-Ab more effectively inhibits tumor growth and pre-
vents tumor relapse than simple combination of two
monospecific antibodies.
Discussion
Breast cancer is one of the most common cancers in
women. It accounts for 22.9% of all cancer cases inwomen
worldwide and was responsible for 13.7% of cancer
deaths in 2008. EGFR and IGF-IR activation contributes
to the initiation and progression of breast cancer. Trastu-
zumab (trastuzumab) has been in clinical use for treat-
ment ofHER2-overexpressing breast cancers, but patients
often develop resistance to the therapy. Thus, there is a
need for novel therapies. In this study, we generated and
tested Bi-Ab, a "knobs-into-holes" Bi-Ab that cotargets
HER2 and IGF-IR, in in vitro assays and in the tumor
xenograft mouse model overexpressing both HER2
and IGF-IR. Our results indicate that cotargeting HER2
and IGF-IR may be of clinical relevance in treating
HER2- and/or IGF-IR–overexpressing human cancers.
This study was promoted by our observation that
m590 synergized with trastuzumab in inhibiting Akt
phosphorylation in MCF-7 cells (Fig. 2B). But when we
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Figure 3. Characterization of Bi-Ab for inhibitory activity in SKOV-3 cell proliferation and ADCC activity in comparison with m590 and trastuzumab alone, or in
combination (Comb). A, inhibition of SKOV-3 cell proliferation in MTT assay. Percentage of inhibition at each antibody concentration was used in
one-way ANOVA statistical analysis to test whether there was significant difference between any two antibodies at the same concentration. Two
paired antibodies with significant difference (, P < 0.001) in percentage of inhibition are indicated. B, percentage of ADCC of the antibodies at 1 and
5 mg/mL. The same ANOVA statistical analysis was done to test whether there was significant difference in percentage of ADCC between any two antibodies
at the same concentration. Percentage of ADCC between Bi-Ab and Comb at 1 mg/mL showed significant difference (, P < 0.05), which is indicated.
Each antibody dilution was tested in triplicate and the assays were repeated once.
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come to SKOV-3 cell line that expressesmuch higher level
of HER2 than MCF-7, the inhibition of Akt and ERK
phosphorylation by antibodies becomes complicated.
This may attribute to two reasons. First, anti-HER2 mAb
trastuzumab downregulates the phosphorylation of Ras,
Raf, MAP–ERK kinase, and MAPK (ERK; ref. 6). ERK
kinase can phosphorylate dual specific phosphatases
Cdc25c. Downregulated ERK phosphorylation reduces
the activity of Cdc25c, resulting in increased phosphory-
lation of RTK, such as IGF-IR. Therefore, although the
MAPKpathway is blocked by trastuzumab, following the
activation of IGF-IR, the PI3K/Akt pathway is triggered,
leading to a compensatory effect, which rescues tumor
cells fromapoptosis. This feedback loopwas first reported
by Prahallad and colleagues (45). We observed the same
phenomenon in this study (Fig. 2D–F). The increased Akt
phosphorylation caused by the feedback loopmakes anti-
IGF-IR mAb m590 less effective in inhibiting Akt phos-
phorylation, especially in the presence of IGF-I (Fig. 2E
and F). Nevertheless, m590 and Bi-Ab inhibit ligand-
induced phosphorylation of IGF-IR in SKOV-3 cells (Fig.
2F), and Bi-Ab inhibits ERK phosphorylation in a dose-
dependentmanner in SKOV-3 cells in the absence of IGF-I
(Fig. 2G). Second, high levels of HER2 and IGF-IR in
SKOV-3 cells may promote the formation of HER2/
IGF-IR heterodimer. Indeed, Browne and colleagues
reported the existence of HER2/IGF-IR complexes in
trastuzumab-resistant breast cancer SKBR3 cells and
found that cotargeting both receptors improved the effi-
cacy of trastuzumab in vitro (37). HER2/IGF-IR hetero-
dimer may be less sensitive to monospecific antibodies,
trastuzumab andm590. To inhibit the signaling of HER2/
IGF-IRheterodimer, Bi-Ab is expected to bemore effective
than Comb because there may be steric hindrance when
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two IgG molecules need to bind simultaneously to the
same heterodimer. Thismay be one of the reasonswhy Bi-
Ab is more effective than Comb in inhibiting cancer cell
proliferation in vitro and tumor growth in the tumor
xenograft mouse model.
Different methodologies have been described to gener-
ate bispecific antibodies by design (42, 46). We took
advantage of the "knobs-into-holes" strategy for generat-
ingBi-Ab (42). Cotransfection of 293F cellswith the "knob"
and "hole" mutant plasmids yielded Bi-Ab. Protein A
affinity-purified Bi-Ab showed a single peak in gel filtra-
tion (data not shown). More importantly, "knobs-into-
holes"mutations located in the CH3 domain did not affect
antibody effector functions, which are mediated mainly
by theCH2domain of antibodies as evidenced by the high
ADCC activity of Bi-Ab. ADCC is an important mecha-
nism of action for therapeutic antibodies in vivo (47–49).
The result from our ADCC assay demonstrates that Bi-Ab
has comparable or slightly enhanced ADCC activity com-
pared with monospecific antibodies, m590 and trastuzu-
mab, and the Comb. Notably, this is the first report
showing that the "knobs-into-holes" strategydidnot affect
ADCC activity of the resultant Bi-Ab. Nude mice have
relatively normal natural killer (NK) cells and human
IgG1 can bind to mouse Fc-g receptor III (FcrRIII, CD16)
on NK cells. Thus, administration of human IgG1s or
human/mouse chimeric antibodies into mice can induce
ADCC and Ab-dependent cellular phagocytosis in NK
cells, polymorphonuclear leukocytes, and macrophages
(50). Both trastuzumab andm590 contain human IgG1 Fc,
therefore, the inhibitory effect observed in this mouse
study may result from Fab-mediated direct effects of the
antibodies and Fc-mediated ADCC and phagocytosis.
In the current mouse study, tumor growth was more
effectively inhibited by Bi-Ab than trastuzumab and
Comb. Out of seven mice in each experimental group, six
mice in the Bi-Ab group were still having low lumines-
cence intensities (below 2-fold of the baseline level) in the
end of the study (day 35 postinoculations of SKOV-3-Luc
cells), whereas this number was four in the Comb group
and one in the trastuzumab group. Although m590 alone
failed to bring the luminescence intensity to such low
level, coadministration ofm590with trastuzumab (Comb)
significantly enhanced the inhibitory effect of trastuzu-
mab. Cotargeting IGF-IR– and HER2-overexpressing
tumor xenografts with Bi-Ab worked even better than
the simple mixture of two monospecific antibodies
(Comb), which may be ascribed to the more effective
inhibition of ERK phosphorylation and ligand-induced
IGF-IR phosphorylation by Bi-Ab in SKOV-3 cells (Fig. 2C
and D), and enhanced ADCC activity of Bi-Ab compared
with Comb. These results indicate that Bi-Ab has superior
antitumor activity compared with the monospecific anti-
bodies aloneor in combination, and cotargetingHER2and
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Figure 5. Inhibition of cancer growth
by Bi-Ab in SKOV-3 HER2- and
IGF-IR–overexpressing xenograft
mouse model in comparison with
m590 and trastuzumab alone, or in
combination (Comb). A, average
luminescence intensity in each
group of mice at different time
point. Logarithmic values of the
average luminescence intensity
were used in ANOVA statistical
analysis to test whether there was
significant difference between any
two groups at the same time point.
Two paired groups with significant
difference (, P < 0.001) are
indicated. B, number of mice in
each group with luminescence
intensity 2-fold higher than the
baseline level.
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IGF-IR with Bi-Ab may be clinically beneficial in mini-
mizing the acquired resistance to the current trastuzumab
therapy.
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